<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7392152\results\search\testTrace\results.xml">
  <result pre="effects and safety limits. Abstract Given the speed of viral" exact="infection" post="spread, repurposing of existing drugs has been given the"/>
  <result pre="to target a specific viral or human protein crucial for" exact="infection" post="with a specific type of virus [1]. Considering the"/>
  <result pre="resulting in antiviral effect [2]. Various steps in the viral" exact="infection" post="have been examined to understand the mechanism of (hydroxy)chloroquineâ€™s"/>
  <result pre="a recent small clinical trial hydroxychloroquine demonstrated moderate effectiveness in" exact="treatment" post="of COVID-19 patients, and the effect was even more"/>
  <result pre="effects on cells are reversible upon the cessation of drug" exact="treatment" post="[20]. In our previous studies on a set of"/>
  <result pre="biological membranes [11]. The importance of intracellular membranes in coronavirus" exact="infection" post="is immense. Firstly, viruses enter the cell by formation"/>
  <result pre="of interacting with cell compartments and processes critical for viral" exact="infection" post="cycle, such as endosomes, lysosomes and membranes in general."/>
  <result pre="myelitis. Arbidol is registered in Russia and China for the" exact="treatment" post="of influenza [24]. It is claimed to inhibit the"/>
  <result pre="possibly occurs via increasing the endosomal pH, and thereby preventing" exact="infection" post="of the cell. The third antiviral, nelfinavir is a"/>
  <result pre="third antiviral, nelfinavir is a protease inhibitor drug approved for" exact="treatment" post="of HIV infection, but also reported effective against a"/>
  <result pre="combination or alone, be capable of reducing the extent of" exact="infection" post="and helping patients avoid serious or long-term illness. Keeping"/>
  <result pre="suitable for repurposing to treat COVID-19 or any future viral" exact="infection" post="epidemics. Declaration of Competing Interest Authors declare no conflicts"/>
  <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseasesPharmacol. Res. Perspect.52017e00293 3SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine"/>
  <result pre="Infect. Dis.3200372272714592603 4VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.220056916115318 5GordonD.E.JangG.M.BouhaddouM.XuJ.ObernierK.WhiteK.M.Oâ€™mearaM.J.RezeljV.V.GuoJ.Z.SwaneyD.L.TumminoT.A.HÃ¼ttenhainR.KaakeR.M.RichardsA.L.TutuncuogluB.FoussardH.BatraJ.HaasK.ModakM.KimM.HaasP.PolaccoB.J.BrabergH.FabiusJ.M.EckhardtM.SoucherayM.BennettM.J.CakirM.McgregorM.J.LiQ.MeyerB.RoeschF.ValletT.Mac KainA.MiorinL.MorenoE.NaingZ.Z.C.ZhouY.PengS.ShiY.ZhangZ.ShenW.KirbyI.T.MelnykJ.E.ChorbaJ.S.LouK.DaiS.A.Barrio-HernandezI.MemonD.Hernandez-ArmentaC.LyuJ.MathyC.J.P.PericaT.PillaK.B.GanesanS.J.SaltzbergD.J.RakeshR.LiuX.RosenthalS.B.CalvielloL.VenkataramananS.Liboy-LugoJ.LinY.HuangX.P.LiuY.WankowiczS.A.BohnM.SafariM.UgurF.S.KohC.SavarN.S.TranQ.D.ShengjulerD.FletcherS.J.Oâ€™nealM.C.CaiY.ChangJ.C.J.BroadhurstD.J.KlippstenS.SharpP.P.WenzellN.A.Kuzuoglu-OzturkD.WangH.Y.TrenkerR.YoungJ.M.CaveroD.A.HiattJ.RothT.L.RathoreU.SubramanianA.NoackJ.HubertM.StroudR.M.FrankelA.D.RosenbergO.S.VerbaK.A.AgardD.A.OttM.EmermanM.JuraN.A SARS-CoV-2 protein interaction map"/>
  <result pre="targets for drug repurposingNature2020 6GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonorÃ©S.ColsonP.ChabriÃ¨reE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trialInt."/>
  <result pre="induction: reliability and warningsJ. Chem. Inf. Model.5320131436144623692521 32NadanacivaS.LuS.GebhardD.F.JessenB.A.PennieW.D.WillY.A high content" exact="screening" post="assay for identifying lysosomotropic compoundsToxicol. In Vitro25201171572321184822 33RorigK.J.RubenZ.AndersonS.N.Structural determinants"/>
  <result pre="hERG1 potassium channelFront. Pharmacol.1201013721833176 39DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.Jr.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs for" exact="treatment" post="of Middle East respiratory syndrome coronavirus infectionAntimicrob. Agents Chemother.5820144885489324841273"/>
  <result pre="of the antiretroviral activity of the CCR5 antagonist Vicriviroc in" exact="treatment" post="experienced HIV-infected subjects (ACTG protocol 5211)J. Acquir. Immune Defic."/>
 </snippets>
</snippetsTree>
